Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

TIGAR (chromosome 12 open reading frame 5)

Written2013-12Helga Simon, Ana Rodríguez-García, Àurea Navarro-Sabaté, Pere Fontova, Ramon Bartrons, Anna Manzano
Departament de Ciencies Fisiologiques II, Campus de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain

(Note : for Links provided by Atlas : click)

Identity

Alias_namesC12orf5
chromosome 12 open reading frame 5
Other aliasFR2BP
HGNC (Hugo) TIGAR
LocusID (NCBI) 57103
Atlas_Id 50684
Location 12p13.32  [Link to chromosome band 12p13]
Location_base_pair Starts at 4321193 and ends at 4360024 bp from pter ( according to hg19-Feb_2009)  [Mapping TIGAR.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
TIGAR (12p13.32) / TIGAR (12p13.32)TIGAR (12p13.32) / TSPAN9 (12p13.33)

DNA/RNA

 
  Figure 1. Schematic representation of TIGAR location in chromosome 12, gene structure and transcript mRNA. Different numbering has been used considering chromosomal, gene or mRNA sequence.
Description The human TIGAR gene is composed of 6 exons spanning genomic region about 50,4 kb (GenBank NC_000012.11). The transcript mRNA is 8,2 kb (GenBank NM_020375.2) and it is composed by the exon regions 5827..5937, 15914..15951, 21673..21794, 34453..34530, 35901..36011 and 36894..44662.
Transcription The human TIGAR coding sequence consists of 813 bp from the start codon to the stop codon. There are no splicing variants reported.
Pseudogene A pseudogene of the ribosomal protein S15 has been located in the region 8981..9473 by computational analysis using a gene prediction method, but there is not experimental data proving it.

Protein

 
  Figure 2. Diagram of TIGAR structure from PDB (entry number: 3DCY). The PDF file does not contain information about the parts of the sequence that are not underlined.
Description Human TIGAR protein consists of 270 aminoacids, with a molecular weight of 30063 Da. It is composed of a bisphosphatase active site in which two histidines, His-11 and His-198, and one glutamic acid, Glu-102, are key residues for its function. TIGAR catalytic domain belongs to the histidine phosphatase superfamily of proteins, a conserved group of proteins which contain a domain with a histidine forming a phosphoenzyme transiently during the catalysis (Rigden, 2008). This domain shares similarity with enzymes of the phosphoglycerate mutase family (PGAM) and with the bisphosphatase domain of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2), in which the three aminoacids in the catalytic domain are conserved.
More information about TIGAR protein can be found in Uniprot Q9NQ88.
Human TIGAR structure contains different motifs as represented in the image below (PDB reference 3DCY).
The crystallized structure of Danio rerio TIGAR is available in PDB (3E9D reference) and was published by Li and Jogl, 2009.
 
  Figure 3. Human TIGAR crystalized structure visualization in Jmol software. His-11 is represented in white, Glu-102 is in purple, His-198 is colored green and C and N terminus are represented in red and blue, respectively. A) General protein view. B) Zoom of the visualization to the catalytic core, with the two histidines represented and the phosphate group painted following the consensus-based coloring of atoms. C) Protein surface and inside-core representation. The central core of the protein is composed by a six-stranded mixed β sheet flanked by α helices on both sides.
Expression TIGAR mRNA is expressed in all the tissues in which it has been analysed and it is overexpressed in several cancer cell lines such as T-lymph Jurkat cancer, kidney HEK-293, liver HuH-7 and HepG2, lung A549, colon RKO, bone U2OS, brain GAMG, prostate LnCap, cervix HeLa and breast MCF7.
All this information can be found in GeneCards (sections proteins and expression).
Localisation TIGAR is mainly localized in the cytoplasm. Under hypoxic conditions, a relocalization of the protein linked to HK-2 (hexokinase 2) in the outer mitochondrial membrane has been described (Mathupala et al., 2009; Cheung et al., 2012).
 
  Figure 4. Schematic representation of TIGAR in metabolic pathways. The main enzymes involved in glycolysis are shown, as well as the substrates and products of TIGAR activity. The pentose phosphate pathway and mitochondrial metabolic pathways have been summarized. HK: hexokinase, PGI: phosphoglucose isomerase, PFKFB3: phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3, PFK-1: phosphofructokinase-1, DHAP: dihydroxyacetone phosphate, GA-3-P: glyceraldehyde 3-phosphate, GAPDH: glyceraldehyde 3-phosphate dehydrogenase, 1,3-BPG: 1,3-bisphosphoglycerate, mTORC1: mammalian target of rapamycin complex 1, PEP: phoshoenolpyruvate, GSH: glutathione.
Function TIGAR was identified by microarray analysis of gene expression after TP53 induction (Bensaad et al., 2006). TIGAR plays a role in the TP53 tumor suppressor program by reducing reactive oxygen species (ROS) levels and preventing DNA damage-induced apoptosis. Their functions are based on glycolysis inhibition and the enhancement of pentose phosphate pathway (PPP).
TIGAR is a bisphosphatase that hydrolyzes Fructose-2,6-bisphosphate to Fructose-6-phosphate, which can enter the PPP to generate NADPH and ribose-5-phosphate, thus, reducing oxidative stress and generating nucleotide precursors (Bensaad et al., 2006).
Beta-D-fructose 2,6-bisphosphate + H2O ⇔ D-fructose 6-phosphate + phosphate
The switch from TP53-induced cell-cycle arrest to apoptosis following maintained stress is associated with downregulation of TIGAR and therefore the loss of P53-dependent survival agents could be the cause of the apoptotic response. It has been proposed that TP53-dependent metabolism regulation could be orchestrated by different mechanisms other than the ones that regulate TP53-induced apoptosis. TIGAR antiapoptotic effects are oxidative-stress dependent. The apoptosis induction by other mechanisms is not affected by TIGAR, as it was shown in IL-3-dependent apoptosis FL5.12 cell line, and in anti-Fas induced apoptosis in U2OS cells, suggesting that TIGAR can modulate apoptosis in a cell-dependent manner (Bensaad et al., 2006).
As described previously, under hypoxic conditions TIGAR is localized in outer mitochondrial membrane. In this situation, it binds together with HK2 to mitochondria (Mathupala et al., 2009) in a HIF1α (hypoxia-inducible factor 1α) dependent manner, and limits ROS levels. If HK2 is not present, oxidative stress reduction by TIGAR is lower. It has been shown that mutant TIGAR TM (Triple Mutant without enzymatic activity: H11A/E102A/H198A) is able to relocalize to mitochondria in response to hypoxia and, indeed, is able to bind to HK2 in the outer mitochondrial membrane. Therefore, the maintenance of mitochondrial membrane potential by TIGAR is independent of its bisphoshatase activity. However, the single deletion of four aminoacids in the C-terminus (258-261) avoided TIGAR mobilization to the mitochondria after hypoxia, although its bisphosphatase activity remained unaltered. The double mutant TM TIGAR/258-261 was not able to reduce ROS levels (Bensaad et al., 2006; Cheung et al., 2012). In conclusion, TIGAR lowers ROS levels both by inhibiting glycolysis and by enhancing an adequate mitochondrial function coupling to HK2.
TIGAR effects have also been related to autophagy as an inhibition of this cell process was described when cells were exposed to stress conditions such as nutrient starvation or metabolic stress, in parallel with an overexpression of TIGAR and a decrease in ROS cell levels. After TIGAR suppression, autophagy was induced to moderate apoptotic response by restraining ROS levels (Bensaad et al., 2009).
The relation between autophagy and apoptosis can be modulated differently depending on the stimulus and cell type. D-galactose (D-gal) treatment of neuroblastoma cells induced necroptosis and autophagy, as shown by upregulation of Bmf, Bnip3, Atg5 and TIGAR, but there were no changes in expression in genes related to apoptosis (Li et al., 2011).
Recently, it has been described a decrease in steady-state mRNA levels of TIGAR when the human hepatocellular carcinoma HepG2 cell line was exposed to high oxidative stress conditions induced by the superoxide radical-generating menadione, hydrogen peroxide (H2O2) or nutrient starvation, in parallel with a down-regulation of the damage-regulated autophagy modulator (DRAM). mRNA levels of both genes were recovered when cells were treated with antioxidants such as GSH or N-acetylcysteine, suggesting a complex regulation of tumor suppressor genes by ROS levels (Kim et al., 2013). In front of a disruption in the homeostasis balance of the cell, TIGAR would provide cytoprotection by its antioxidant properties rather than its ability to inhibit autophagy. After a threatening stimulus, a rapid increase in the autophagic flux occurs mostly regulated by post-translational modifications, followed by a transcriptionally-mediated delayed autophagyc response phase, in which TP53 would be activated. In this context, TIGAR would be rapidly transactivated and would mediate its antioxidant response, while autophagy is enhanced by other transcriptionally activated targets, such as DRAM (Pietrocola et al., 2013). Some authors have proposed a TP53-orchestrated mechanism by which this protein would regulate stress-induced autophagy by balancing two proteins with opposite effects: TIGAR and DRAM (Dewaele et al., 2010; Zhang et al., 2010).
In TP53 knock-out mice (TP53-/-) cardioprotection against ischemic injury and resistance to cardiac remodeling were observed, and a significant TIGAR overexpression was described. The TIGAR knock-out (TIGAR-/-) had the same effects and a TP53-dependent mechanism of autophagy inhibition through the mitophagy enhancer Bnip3 was described. Double knock-out of TP53 and TIGAR mice exposed to ischemia responded with an increase in ROS levels, followed by an overexpression of Bnip3 that lead to mitophagy and, thus, cardioprotection. The activation of Bnip3 and mitophagy was recovered by NAC, confirming that TIGAR-mediated mitophagy inhibition is mediated by ROS. Ventricular remodeling after myocardial infarction is a consequence of both impaired mitochondrial integrity and enhanced apoptosis, whereas mitophagy helps cells to undergo mitochondrial damage and avoid apoptosis, resulting in a diminished initial infarct size, less ventricular remodeling and restored homeostasis in ischemic myocardium (Kimata et al., 2010; Hoshino et al., 2012).
The analysis of lung tissues from idiopathic pulmonary fibrosis patients revealed decreased autophagyc activity, evidenced by less LC3 and p62 expression. When these cells were treated with TGFβ in vitro, impairment in autophagy was observed, in parallel with an increase in TIGAR expression, although the possible mechanism connecting TGFβ and TIGAR was not described (Patel et al., 2012).
In a co-culture system, Martinez-Outschoorn et al. showed that oxidative stress-induced autophagy correlated with Cav-1 downregulation in cancer associated fibroblasts, and with overexpression of TIGAR in adjacent cancer cells. Consequently, autophagy cancer associated fibroblasts provide recycled nutrients for cancer cell metabolism and, moreover, prevent cancer cells death by upregulating TIGAR and thus conferring resistance to apoptosis and autophagy (Martinez-Outschoorn et al., 2010). Further studies by the same group demonstrated that the metabolic coupling between cancer cells and fibroblasts can explain tamoxifen resistance as cancer associated fibroblasts enhance the activity of TIGAR in cancer cells, providing protection against tamoxifen-induced apoptosis, which was much higher in monocultures of cancer cells alone (Martinez-Outschoorn et al., 2011). In another study, glutamine was described as a needed factor for Cav-1 downregulation in cancer associated fibroblasts and for the decrease in autophagy mediators and markers in cancer cells, establishing a model in which autophagy fibroblasts may serve as a source of glutamine to fuel cancer cell mitochondrial activity. Therefore, a cycle between catabolic tumor stroma cells and anabolic tumor cells has been proposed to explain the relations between cells in tumor environment (Ko et al., 2011).
Besides, TIGAR has also been proposed to be an anticancer therapy target gene considering that autophagy inhibition in cancer cells would probably increase cell death (Dodson et al., 2013).
All these studies confirm that TIGAR functions are not only restricted to glycolysis regulation, as this protein plays key roles in different cell processes involving oxidative stress restriction.

Activation and regulation
TIGAR belongs to that group of TP53 target genes that become rapidly activated by low levels of stress. There are two possible TP53 binding sites in TIGAR gene: one upstream of the first exon (BS1) and one within the 1st intron (BS2), which is the most efficient one and has been validated by chromatin immunoprecipitation (ChIP) analysis (Bensaad et al., 2006).
In an experimental approach, TIGAR was induced by Actinomycin D and Adriamycin (Bensaad et al., 2006), two well-known activators of TP53, and also by Nutlin-3a, an antagonist of Mdm2 (Hasegawa et al., 2009). Other stimuli that have been described to trigger TIGAR expression are radiotherapy (Peña-Rico et al., 2011), glutamine (Ko et al., 2011), chemotherapy (Madan et al., 2012), UV light (Madan et al., 2012), TNFα and radiotherapy mimetics (Sinha et al., 2013).
When DNA damage occurs, TP53 is expressed either to repair DNA or lead the cell towards apoptosis. High ROS levels can compromise DNA stability which, in turn, could help cells to accumulate mutations and become tumorigenic. As TIGAR reduces ROS levels, it has been proposed as a tumor suppressor gene, although it should be taken into account that, as TIGAR can help tumor cells survival, it could act as an oncogene in some situations. TP53 is able to suppress tumor development when mechanisms of apoptosis, senescence and cell-cycle arrest are impeded. This supports the idea that metabolism, and thereby TIGAR, has a key role in cancer development (Li et al., 2012; Valente et al., 2013).
TIGAR expression can also be modulated in a TP53 independent manner, as results from studies with the TP53 null T98G and H1299 cell lines suggest (Bensaad et al., 2006; Peña-Rico et al., 2011). The mechanisms implicated in the regulation of TIGAR expression in the absence of TP53 are unclear. The CRE-binding protein (CREB) has been described to regulate TIGAR expression through a CRE-binding site at the TIGAR promoter, which was first annotated by bioinformatic analysis and then confirmed by electrophoretic mobility shift assay (EMSA) and ChIP. CREB knockdown reduced enhanced promoter activity and TIGAR expression; whereas CREB overexpression resulted in enhanced promoter activity and TIGAR expression levels (Zou et al., 2013). Another transcription factor, SP1, was found to bind to TIGAR promoter in a SP1-binding site located in a very short region (-56/-4) both in vitro and in vivo, and was considered a key factor for proper basal activity of TIGAR promoter (Zou et al., 2012). Recently, some authors have identified HIF-1α as a potential regulator of SCO2 and TIGAR gene expression suggesting the involvement of P300/CBP-associated factor (PCAF) in differential recruitment of HIF-1α and p53 to the promoter of TIGAR and/or SCO2 genes in response of hypoxia in tumoral cells (Rajendran et al., 2013).

Chromosomal rearrangements: copy number variants
Some alterations affecting TIGAR genome region have been described in patients, some of them showed phenotypic effects. Gain of 12:189578-34178209 resulted in hydronephrosis, micrognathia, edema, depressed nasal bridge, tricuspid regurgitation and diaphragmatic eventration. Patients with gain of 12:189561-41878937 suffered global developmental delay. The ones with gain of 12:230361-20643702 showed intellectual disability and electroencephalogram with localized low amplitude activity, whereas gain of 12:191619-8327369 resulted in macroencephaly, visual impairment, intellectual disability, muscular hipotonia, and seizures.
For more information, see DECIPHER.

Homology Location in the mouse: chromosome 6, 61.92 cM, 127085116-127109550 bp, complement strand (MGI).
For a comparison of the gene among Homo sapiens, mouse, rat, chimpanzee, cattle, rhesus macaque, dog, chicken and zebrafish see MGI.
For all species known gene tree, see: Treefam database.

 

Mutations

Note There have been observed 22 somatic mutations in patient tumor samples collected in the COSMIC database.
Nonsense substitutions: 1, located in c.466G>T (p.G156*).
Missense substitutions: 16, which represent 82% of the mutations described among all patients. Only two missense substitutions have been found in more than one patient: c.268A>G (p.R90G) was found in 5 patients and c.215G>T (p.R72I) was found in 2 patients.
Synonymous substitutions: 4.
No deletions, insertions or chromosomal fusions in TIGAR gene have been described in any tumor sample.

Genomic variants
There are 878 SNP variants described but none of them have clinical significance described (GeneCards).

 
  Figure 6. Histogram of mutations found among the aminoacid sequence of TIGAR protein. The maximum number of substitutions at any specific genomic region is represented in Y axis. R90G is the most common aminoacid substitution, caused by 5 different genomic mutations. Histidine phosphatase family homolog domain is represented in green and copy number variants are represented in blue (gain of function) and red (loss of function). Adapted from: COSMIC Database.

Implicated in

Note
  
Entity Various cancers
Prognosis Despite that little is known about the implication of TIGAR in cancer, there are some authors that point out about the importance of p53 targets such as cytochrome c oxidase 2 (SCO2) or TIGAR in the prognosis of breast cancer patients. Some studies indicated that p53, the most commonly mutated tumor suppressor gene, may have important functions in the regulation of energy-generating metabolic pathways that switch from oxidative phosphorylation to glycolysis via the synthesis of SCO2 and TIGAR (Won et al., 2012).
Oncogenesis The p53 tumor suppressor pathway coordinates DNA repair, cell-cycle arrest, apoptosis, and senescence to preserve genomic stability and prevent tumor formation. TIGAR has been identified as a p53-inducible gene. TIGAR expression lowers fructose-2,6-bisphosphate levels in cells, resulting in an inhibition of glycolysis and an overall decrease in ROS levels. These functions of TIGAR correlate with an ability to protect cells from ROS-associated apoptosis, and consequently, knockdown of endogenous TIGAR expression sensitizes cells to p53-induced death. Expression of TIGAR may therefore modulate the apoptotic response to p53, allowing survival in the face of mild or transient stress signals that may be reversed or repaired. The decrease of intracellular ROS levels in response to TIGAR may also play a role in the ability of p53 to protect from the accumulation of genomic damage (Bensaad et al., 2006). In an in vitro model of nasopharyngeal cancer, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl) cytosine (ECyd), a RNA-nucleoside anti-metabolite with potent anticancer activity, acts by downregulating TIGAR and depleting NADPH. The overexpression of TIGAR was able to rescue cells from ECyd-induced growth inhibition, demonstrating a novel mechanistic action of ECyd on TIGAR. This study suggests a novel link between RNA metabolism and TIGAR regulation (Lui et al., 2010). In human cervical carcinoma cells, RNAi-mediated citrate synthase knockdown accelerated cancer cell metastasis and proliferation being these effects related to deregulation of the p53/TIGAR and SCO2 pathways (Lin et al., 2012). In other studies, TIGAR also mediates de-phosphorylation of RB (retinoblastoma) and stabilisation of RB-E2F1 complex thus delaying the entry of cells in S phase of the cell cycle. Thus, TIGAR inhibits proliferation of cancer cells and increases drug-mediated tumour regression by promoting p53-mediated cell-cycle arrest (Madan et al., 2011; Madan et al., 2012).
  
  
Entity Hepatic cancer
Note Silencing TIGAR by RNAi induces apoptotic and autophagy cell death in HepG2 cells, and this data raise hope for the future successful application of TIGAR siRNA in patients with hepatocellular carcinoma (HCC) (Ye et al., 2013).
  
  
Entity Breast cancer
Note In a model of MCF7 breast cancer cells co-cultured with non-transformed fibroblasts, glutamine protects MCF7 cells against apoptosis, via the upregulation of the anti-apoptotic and anti-autophagic protein TIGAR (Martinez-Outschoorn et al., 2011). The authors showed that glutamine cooperates with stromal fibroblasts to confer tamoxifen-resistance in MCF7 cancer cells (Ko et al., 2011). Moreover, Won et al. (2012) have analysed the expression of p53, SCO2, TIGAR, and COX in 113 cases of invasive breast cancer using immunohistochemistry. A high expression of p53, SCO2, TIGAR, and COX was noted in 27,5% (31 cases), 84,1% (95 cases), 74,3% (84 cases), and 73,4% (83 cases) of the breast tumors, respectively. A high p53 expression was significantly associated with low expression levels of SCO2 (P = .008), COX (P < .0001), and TIGAR (P = .007). These results suggest that p53 can modulate the metabolic pathways via the proteins SCO2 and TIGAR in human breast cancer. TIGAR and p53 can lower the cellular sensitivity to ROS-associated apoptosis, and this potentially contributes to the survival of cells undergoing mild, reversible stress by different anti-tumoral drugs (Won et al., 2012).
  
  
Entity Head and neck cancer
Note In a nasopharyngeal cancer, the onco-protein kinase c-Met maintains TIGAR expression. Inhibition of c-Met resulted in significant downregulation of TIGAR and subsequent depletion of intracellular NADPH. The results provide the first evidence linking c-Met, TIGAR and NADPH regulation in human cancer cells suggesting that inhibition of a tyrosine kinase/TIGAR/NADPH cascade may have therapeutic applicability in human cancers (Lui et al., 2011).
  
  
Entity Lung cancer
Note Sinthupibulyakit et al. (2010) have shown that a glycolytic inhibitor, 2-deoxy-D-glucose (2DG), exhibits a cytotoxic effect on non-small cell lung cancer in a p53-dependent manner. 2DG significantly inhibits ATP production in p53-deficient lung cancer cells (H358) but not in p53-wt cells (A549). This effect is explained by the ROS increase from OXPHOS that induces the expression of p53 antioxidants targets such as cytochrome c oxidase 2 (SCO2) and TIGAR. Therefore, killing of cancer cells by this inhibitor of glycolysis is more efficient in cancer cells without functional p53 that protects against metabolic stress by up-regulation of TIGAR (Sinthupibulyakit et al., 2010).
Other authors point out the importance of autophagy as a cellular homeostatic process to determine cell fate decisions under conditions of stress. Deregulation of autophagy impacts numerous human diseases including cancer and chronic lung diseases. TIGAR could be implicated in the impairment of autophagy by TGF-β(1) and may represent a mechanism for the promotion of fibrogenesis in idiopathic pulmonary fibrosis (Patel et al., 2012).
  
  
Entity Intestinal cancer and ulcerative colitis
Note The ability of TIGAR to contribute to the growth and survival of cells in rapidly proliferating tissue suggested a possible contribution of TIGAR to the development or progression of malignancies. In a mouse model of intestinal tumor induced by deletion of APC in the intestinal stem cells, TIGAR expression was increased and a reduction in tumor development and an enhancement of survival in TIGAR-/- mice were described. Furthermore, using an in vitro organoid culture model, impaired growth of TIGAR-/- cells derived from the crypt of the small intestine was rescued by supplementation with nucleosides and the antioxidant N-acetyl cysteine In the other hand, in a mouse model of ulcerative colitis TIGAR plays an important role in tissue regeneration and that lack of TIGAR results in a failure to repair damaged intestinal epithelium. TIGAR is overexpressed in crypts during the recovery of proliferation in WT mice. The lack of TIGAR results in a failure to repair damaged intestinal epithelium and increase in oxidative damage. In these systems, therefore, TIGAR expression is necessary to maintain normal healthy tissues following stress or damage. Therefore, while loss of TIGAR is deleterious to the recovery from intestinal damage, lack of TIGAR becomes advantageous under conditions where enhanced proliferation occurs in the context of tumor development and progression of malignancies. In conclusion, TIGAR is not required for normal tissue growth and development but becomes important in supporting rapid proliferation in adult intestinal epithelium (Cheung et al., 2013).
  
  
Entity Multiple myeloma
Note Multiple myeloma cells present problems in the expression of oncoprotein MUC1-C. The inhibition of MUC1-C increases ROS and is also associated with down-regulation of TIGAR, resulting in the decrease in NADPH and glutathione (GSH) levels. The suppression of TIGAR and NADPH levels contributes to ROS-mediated apoptosis/necrosis of multiple myeloma cells. These findings indicate that multiple myeloma cells are dependent on MUC1-C and TIGAR for maintenance of redox balance and that targeting MUC1-C activates a cascade involving TIGAR suppression that contributes to multiple myeloma cell death (Yin et al., 2012).
  
  
Entity Chronic lymphocytic leukemia
Note In chronic lymphocytic leukemia a correlation between sensitivity to fludarabine and TIGAR induction mediated by p53 was described. The sensitivity of fludarabine was variable despite all patients analysed had wild type p53 (López-Guerra et al., 2008).
  
  
Entity Cervix carcinoma
Note In human cervical carcinoma cells, RNAi-mediated citrate synthase inhibition accelerated cancer cell proliferation and metastasis in in vitro assays and in vivo tumor xenograft models. The main effects of this knockdown are related with severe defects in respiratory activity and marked decreases in ATP production, but increases in glycolytic metabolism, resulted from deregulation of the p53/TIGAR and SCO2 pathways. This phenotypic change was completely reversed by p53 reactivation suggesting the implication of TIGAR in this malignant proliferation (Lin et al., 2012).
  
  
Entity Glioblastoma
Note Wanka et al. (2012) have shown in glioblastoma that TIGAR is overexpressed and its expression reduces cell death induced by glucose and oxygen restriction. Metabolic analyses reveal that TIGAR inhibits glycolysis and promotes respiration. Further, generation of ROS is reduced whereas levels of reduced GSH are elevated in TIGAR-expressing cells (Wanka et al., 2012). These results agree with the potential of TIGAR as an antitumoral target demonstrated by Peña-Rico et al. (2011), who analysed the effects of TIGAR knockdown in U87MG and T98G glioblastoma-derived cell lines and concluded that TIGAR abrogation provides a novel adjunctive therapeutic strategy against glial tumors by increasing radiation-induced cell impairment, thus allowing the use of lower radiotherapeutic doses. Gliomas are resistant to radiation therapy, as well as to TNFα induced killing. Radiation-induced TNFα triggers Nuclear Factor κB (NFκB)-mediated radioresistance. The existence of ATM-NFκB axis that regulates the metabolic modulator TIGAR suggests its implication in the mechanisms through which inflammation could affect resistance and adaptation to radiomimetics despite concurrent induction of death (Sinha et al., 2013).
Recently, in a neuroblastoma SH-SY5Y cell model a novedous sonodynamic therapy has been assayed. This noninvasive modality for cancer treatment is based on the selective activation of a sonosensitizer agent by acoustic cavitation. The activated sonosensitizer agent might generate reactive oxygen species leading to cancer cell death. This therapy showed a significant decrease in SH-SY5Y cell proliferation in vitro in two and three-dimensional neuroblastoma models and this effect was accompanied by a significant decrease in the TIGAR mRNA expression 24 hours after sonodynamic treatment (Canaparo et al., 2013).
  
  
Entity Alzheimer's disease and neurodegeneration
Note Some authors reported that TIGAR protein levels were decreased in various stages of Alzheimer's disease dementia severity, suggesting diminishing effect of ATM-p53 signalling in counteracting cell death induced by glycolysis/OXPHOS. The progressive decrease of TIGAR expression reported agrees with the findings of altered post-translational modification of TP53, which result in increased formation of functionally inactive TP53 monomers and dimers, but not functionally active TP53 tetramers in Alzheimer's disease patients' brains (Di Domenico et al., 2009; Katsel et al., 2013). Moreover, the reported elevated expression of conformationally altered unfolded TP53 in peripheral blood cells from patients with Alzheimer's disease (Uberti et al., 2008) raises the question of the impact of protein structural changes on the TP53 activity during progression of dementia. TP53 activates TIGAR under low levels of stress. However, following extended exposure to stress and the induction of the TP53-mediated apoptotic response, TIGAR expression is reduced, suggesting that the induction of the apoptotic response may reflect the loss of protection by the TP53-inducible survival signals (Bensaad et al., 2006). Therefore, TIGAR may play a critical role in the switch of TP53-induced responses to stress and a decrease in its expression may have negative consequences for the survival of cells during progression of dementia (Madan et al., 2012).
  
  
Entity Diabetes and obesity
Note Studies performed in rats with diabetes mellitus to evaluate the potential role of p53 and its transcriptional targets in exercise-induced mitochondrial adaptation in skeletal muscle showed a decrease in p53 and TIGAR protein levels, indicating that exercise training can attenuate oxidative stress and increase mitochondrial DNA content in skeletal muscle. Agreeing with these results, suppression of p53 and TIGAR expression could play a role in preventing oxidative stress in insulin resistance (Qi et al., 2011).
In the same direction Derdak et al. (2011) reported that susceptibility to ethanol-induced liver damage in different rat strains and the promotion of insulin resistance is correlated with p53 activation and the activation of TIGAR.
  

To be noted

Conclusion: In summary, since TIGAR was discovered in 2006 as a p53 target activated in response to moderated stress, several functions related to its fructose2,6-bisphosphatase activity have been described. TIGAR has become a key protein in the regulation of cell processes such as apoptosis, autophagy, DNA repair and control of oxidative stress, determining the fate of the cell in response to different insults. The role of TIGAR in maintaining tumor cell survival is highlighted by the fact that some tumor types have elevated levels of TIGAR expression (Wanka et al., 2012; Won et al., 2012) and the inhibition of different therapeutic targets is associated with a decrease of TIGAR expression. TIGAR can helps to support tumorigenesis by limiting ROS and providing precursors for nucleotide synthesis. These data predict that inhibition of TIGAR may carry therapeutic advantage in cancer treatments as demonstrated in different cancer models (Peña et al., 2011; Martinez-Outschoorn et al., 2011; Cheung et al., 2013).

Bibliography

Modulation of intracellular ROS levels by TIGAR controls autophagy.
Bensaad K, Cheung EC, Vousden KH.
EMBO J. 2009 Oct 7;28(19):3015-26. doi: 10.1038/emboj.2009.242. Epub 2009 Aug 27.
PMID 19713938
 
TIGAR, a p53-inducible regulator of glycolysis and apoptosis.
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH.
Cell. 2006 Jul 14;126(1):107-20.
PMID 16839880
 
Metabolic regulation by p53 family members.
Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH.
Cell Metab. 2013 Nov 5;18(5):617-33. doi: 10.1016/j.cmet.2013.06.019. Epub 2013 Aug 15.
PMID 23954639
 
Polymeric nanoparticles enhance the sonodynamic activity of meso-tetrakis (4-sulfonatophenyl) porphyrin in an in vitro neuroblastoma model.
Canaparo R, Varchi G, Ballestri M, Foglietta F, Sotgiu G, Guerrini A, Francovich A, Civera P, Frairia R, Serpe L.
Int J Nanomedicine. 2013;8:4247-63. doi: 10.2147/IJN.S51070. Epub 2013 Nov 6.
PMID 24232189
 
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
Cheung EC, Athineos D, Lee P, Ridgway RA, Lambie W, Nixon C, Strathdee D, Blyth K, Sansom OJ, Vousden KH.
Dev Cell. 2013 Jun 10;25(5):463-77. doi: 10.1016/j.devcel.2013.05.001. Epub 2013 May 30.
PMID 23726973
 
Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death.
Cheung EC, Ludwig RL, Vousden KH.
Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20491-6. doi: 10.1073/pnas.1206530109. Epub 2012 Nov 26.
PMID 23185017
 
Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.
Dai Q, Yin Y, Liu W, Wei L, Zhou Y, Li Z, You Q, Lu N, Guo Q.
Int J Biochem Cell Biol. 2013 Jul;45(7):1468-78. doi: 10.1016/j.biocel.2013.04.015. Epub 2013 Apr 21.
PMID 23612020
 
Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease.
Derdak Z, Lang CH, Villegas KA, Tong M, Mark NM, de la Monte SM, Wands JR.
J Hepatol. 2011 Jan;54(1):164-72. doi: 10.1016/j.jhep.2010.08.007. Epub 2010 Sep 6.
PMID 20961644
 
ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy.
Dewaele M, Maes H, Agostinis P.
Autophagy. 2010 Oct;6(7):838-54. Epub 2010 Oct 19. (REVIEW)
PMID 20505317
 
Glutathionylation of the pro-apoptotic protein p53 in Alzheimer's disease brain: implications for AD pathogenesis.
Di Domenico F, Cenini G, Sultana R, Perluigi M, Uberti D, Memo M, Butterfield DA.
Neurochem Res. 2009 Apr;34(4):727-33. doi: 10.1007/s11064-009-9924-9. Epub 2009 Feb 6.
PMID 19199029
 
Cellular metabolic and autophagic pathways: traffic control by redox signaling.
Dodson M, Darley-Usmar V, Zhang J.
Free Radic Biol Med. 2013 Oct;63:207-21. doi: 10.1016/j.freeradbiomed.2013.05.014. Epub 2013 May 20. (REVIEW)
PMID 23702245
 
Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S.
Leukemia. 2009 Nov;23(11):2090-101. doi: 10.1038/leu.2009.171. Epub 2009 Aug 27.
PMID 19710698
 
p53-TIGAR axis attenuates mitophagy to exacerbate cardiac damage after ischemia.
Hoshino A, Matoba S, Iwai-Kanai E, Nakamura H, Kimata M, Nakaoka M, Katamura M, Okawa Y, Ariyoshi M, Mita Y, Ikeda K, Ueyama T, Okigaki M, Matsubara H.
J Mol Cell Cardiol. 2012 Jan;52(1):175-84. doi: 10.1016/j.yjmcc.2011.10.008. Epub 2011 Oct 18.
PMID 22044588
 
Cycle checkpoint abnormalities during dementia: a plausible association with the loss of protection against oxidative stress in Alzheimer's disease.
Katsel P, Tan W, Fam P, Purohit DP, Haroutunian V.
PLoS One. 2013 Jul 5;8(7):e68361. doi: 10.1371/journal.pone.0068361. Print 2013.
PMID 23861893
 
Reactive oxygen species-dependent down-regulation of tumor suppressor genes PTEN, USP28, DRAM, TIGAR, and CYLD under oxidative stress.
Kim SJ, Jung HJ, Lim CJ.
Biochem Genet. 2013 Dec;51(11-12):901-15. doi: 10.1007/s10528-013-9616-7. Epub 2013 Jul 6.
PMID 23832602
 
p53 and TIGAR regulate cardiac myocyte energy homeostasis under hypoxic stress.
Kimata M, Matoba S, Iwai-Kanai E, Nakamura H, Hoshino A, Nakaoka M, Katamura M, Okawa Y, Mita Y, Okigaki M, Ikeda K, Tatsumi T, Matsubara H.
Am J Physiol Heart Circ Physiol. 2010 Dec;299(6):H1908-16. doi: 10.1152/ajpheart.00250.2010. Epub 2010 Oct 8.
PMID 20935145
 
Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance.
Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia F, Lisanti MP, Martinez-Outschoorn UE.
Cancer Biol Ther. 2011 Dec 15;12(12):1085-97. doi: 10.4161/cbt.12.12.18671. Epub 2011 Dec 15.
PMID 22236876
 
Structural and biochemical studies of TIGAR (TP53-induced glycolysis and apoptosis regulator).
Li H, Jogl G.
J Biol Chem. 2009 Jan 16;284(3):1748-54. doi: 10.1074/jbc.M807821200. Epub 2008 Nov 17.
PMID 19015259
 
D-galactose induces necroptotic cell death in neuroblastoma cell lines.
Li N, He Y, Wang L, Mo C, Zhang J, Zhang W, Li J, Liao Z, Tang X, Xiao H.
J Cell Biochem. 2011 Dec;112(12):3834-44. doi: 10.1002/jcb.23314.
PMID 21826710
 
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence.
Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W.
Cell. 2012 Jun 8;149(6):1269-83. doi: 10.1016/j.cell.2012.04.026.
PMID 22682249
 
Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy.
Lin CC, Cheng TL, Tsai WH, Tsai HJ, Hu KH, Chang HC, Yeh CW, Chen YC, Liao CC, Chang WT.
Sci Rep. 2012;2:785. doi: 10.1038/srep00785. Epub 2012 Nov 8.
PMID 23139858
 
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
Lopez-Guerra M, Trigueros-Motos L, Molina-Arcas M, Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D, Pastor-Anglada M.
Haematologica. 2008 Dec;93(12):1843-51. doi: 10.3324/haematol.13186. Epub 2008 Oct 22.
PMID 18945750
 
An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.
Lui VW, Lau CP, Cheung CS, Ho K, Ng MH, Cheng SH, Hong B, Tsao SW, Tsang CM, Lei KI, Yamasaki Y, Mita A, Chan AT.
Biochem Pharmacol. 2010 Jun 15;79(12):1772-80. doi: 10.1016/j.bcp.2010.02.012. Epub 2010 Feb 26.
PMID 20219441
 
Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.
Lui VW, Wong EY, Ho K, Ng PK, Lau CP, Tsui SK, Tsang CM, Tsao SW, Cheng SH, Ng MH, Ng YK, Lam EK, Hong B, Lo KW, Mok TS, Chan AT, Mills GB.
Oncogene. 2011 Mar 3;30(9):1127-34. doi: 10.1038/onc.2010.490. Epub 2010 Nov 8.
PMID 21057531
 
TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.
Madan E, Gogna R, Kuppusamy P, Bhatt M, Pati U, Mahdi AA.
Br J Cancer. 2012 Jul 24;107(3):516-26. doi: 10.1038/bjc.2012.260. Epub 2012 Jul 10.
PMID 22782351
 
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP.
Cancer Biol Ther. 2011 Nov 15;12(10):924-38. doi: 10.4161/cbt.12.10.17780. Epub 2011 Nov 15.
PMID 22041887
 
Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.
Mathupala SP, Ko YH, Pedersen PL.
Semin Cancer Biol. 2009 Feb;19(1):17-24. doi: 10.1016/j.semcancer.2008.11.006. Epub 2008 Dec 3. (REVIEW)
PMID 19101634
 
Control of glycolysis through regulation of PFK1: old friends and recent additions.
Mor I, Cheung EC, Vousden KH.
Cold Spring Harb Symp Quant Biol. 2011;76:211-6. doi: 10.1101/sqb.2011.76.010868. Epub 2011 Nov 17. (REVIEW)
PMID 22096029
 
Autophagy in idiopathic pulmonary fibrosis.
Patel AS, Lin L, Geyer A, Haspel JA, An CH, Cao J, Rosas IO, Morse D.
PLoS One. 2012;7(7):e41394. doi: 10.1371/journal.pone.0041394. Epub 2012 Jul 18.
PMID 22815997
 
TP53 induced glycolysis and apoptosis regulator (TIGAR) knockdown results in radiosensitization of glioma cells.
Pena-Rico MA, Calvo-Vidal MN, Villalonga-Planells R, Martinez-Soler F, Gimenez-Bonafe P, Navarro-Sabate A, Tortosa A, Bartrons R, Manzano A.
Radiother Oncol. 2011 Oct;101(1):132-9. doi: 10.1016/j.radonc.2011.07.002. Epub 2011 Aug 22.
PMID 21864926
 
Regulation of autophagy by stress-responsive transcription factors.
Pietrocola F, Izzo V, Niso-Santano M, Vacchelli E, Galluzzi L, Maiuri MC, Kroemer G.
Semin Cancer Biol. 2013 Oct;23(5):310-22. doi: 10.1016/j.semcancer.2013.05.008. Epub 2013 May 30.
PMID 23726895
 
Exercise training attenuates oxidative stress and decreases p53 protein content in skeletal muscle of type 2 diabetic Goto-Kakizaki rats.
Qi Z, He J, Zhang Y, Shao Y, Ding S.
Free Radic Biol Med. 2011 Apr 1;50(7):794-800. doi: 10.1016/j.freeradbiomed.2010.12.022. Epub 2010 Dec 23.
PMID 21185935
 
Acetylation mediated by the p300/CBP-associated factor determines cellular energy metabolic pathways in cancer.
Rajendran R, Garva R, Ashour H, Leung T, Stratford I, Krstic-Demonacos M, Demonacos C.
Int J Oncol. 2013 Jun;42(6):1961-72. doi: 10.3892/ijo.2013.1907. Epub 2013 Apr 17.
PMID 23591450
 
The histidine phosphatase superfamily: structure and function.
Rigden DJ.
Biochem J. 2008 Jan 15;409(2):333-48. (REVIEW)
PMID 18092946
 
ATM-NFkB axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNFa.
Sinha S, Ghildiyal R, Mehta VS, Sen E.
Cell Death Dis. 2013 May 2;4:e615. doi: 10.1038/cddis.2013.128.
PMID 23640457
 
p53 Protects lung cancer cells against metabolic stress.
Sinthupibulyakit C, Ittarat W, St Clair WH, St Clair DK.
Int J Oncol. 2010 Dec;37(6):1575-81.
PMID 21042727
 
Conformationally altered p53: a putative peripheral marker for Alzheimer's disease.
Uberti D, Lanni C, Racchi M, Govoni S, Memo M.
Neurodegener Dis. 2008;5(3-4):209-11. doi: 10.1159/000113704. Epub 2008 Mar 6. (REVIEW)
PMID 18322392
 
p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.
Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A.
Cell Rep. 2013 May 30;3(5):1339-45. doi: 10.1016/j.celrep.2013.04.012. Epub 2013 May 9.
PMID 23665218
 
Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis.
Wanka C, Steinbach JP, Rieger J.
J Biol Chem. 2012 Sep 28;287(40):33436-46. Epub 2012 Aug 10.
PMID 22887998
 
Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer.
Won KY, Lim SJ, Kim GY, Kim YW, Han SA, Song JY, Lee DK.
Hum Pathol. 2012 Feb;43(2):221-8. doi: 10.1016/j.humpath.2011.04.021. Epub 2011 Aug 4.
PMID 21820150
 
Knockdown of TIGAR by RNA interference induces apoptosis and autophagy in HepG2 hepatocellular carcinoma cells.
Ye L, Zhao X, Lu J, Qian G, Zheng JC, Ge S.
Biochem Biophys Res Commun. 2013 Jul 26;437(2):300-6. doi: 10.1016/j.bbrc.2013.06.072. Epub 2013 Jun 28.
PMID 23817040
 
Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.
Yin L, Kosugi M, Kufe D.
Blood. 2012 Jan 19;119(3):810-6. doi: 10.1182/blood-2011-07-369686. Epub 2011 Nov 23.
PMID 22117045
 
The role of p53 in cell metabolism.
Zhang XD, Qin ZH, Wang J.
Acta Pharmacol Sin. 2010 Sep;31(9):1208-12. doi: 10.1038/aps.2010.151. Epub 2010 Aug 23. (REVIEW)
PMID 20729871
 
SP1 plays a pivotal role for basal activity of TIGAR promoter in liver cancer cell lines.
Zou S, Gu Z, Ni P, Liu X, Wang J, Fan Q.
Mol Cell Biochem. 2012 Jan;359(1-2):17-23. doi: 10.1007/s11010-011-0993-0. Epub 2011 Jul 15.
PMID 21761199
 
CREB, another culprit for TIGAR promoter activity and expression.
Zou S, Wang X, Deng L, Wang Y, Huang B, Zhang N, Fan Q, Luo J.
Biochem Biophys Res Commun. 2013 Oct 4;439(4):481-6. doi: 10.1016/j.bbrc.2013.08.098. Epub 2013 Sep 11.
PMID 24036271
 

Citation

This paper should be referenced as such :
Simon, H ; Rodríguez-García, A ; Navarro-Sabatéa, À ; Fontova, P ; Bartrons, R ; Manzano, A
C12orf5 (chromosome 12 open reading frame 5)
Atlas Genet Cytogenet Oncol Haematol. 2014;18(7):500-510.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/C12orf5ID50684ch12p13.html


External links

Nomenclature
HGNC (Hugo)TIGAR   1185
Cards
AtlasC12orf5ID50684ch12p13
Entrez_Gene (NCBI)TIGAR  57103  TP53 induced glycolysis regulatory phosphatase
AliasesC12orf5; FR2BP
GeneCards (Weizmann)TIGAR
Ensembl hg19 (Hinxton)ENSG00000078237 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000078237 [Gene_View]  chr12:4321193-4360024 [Contig_View]  TIGAR [Vega]
ICGC DataPortalENSG00000078237
TCGA cBioPortalTIGAR
AceView (NCBI)TIGAR
Genatlas (Paris)TIGAR
WikiGenes57103
SOURCE (Princeton)TIGAR
Genetics Home Reference (NIH)TIGAR
Genomic and cartography
GoldenPath hg38 (UCSC)TIGAR  -     chr12:4321193-4360024 +  12p13.32   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)TIGAR  -     12p13.32   [Description]    (hg19-Feb_2009)
EnsemblTIGAR - 12p13.32 [CytoView hg19]  TIGAR - 12p13.32 [CytoView hg38]
Mapping of homologs : NCBITIGAR [Mapview hg19]  TIGAR [Mapview hg38]
OMIM610775   
Gene and transcription
Genbank (Entrez)AJ272206 AK313226 AM392615 AY425618 BC012340
RefSeq transcript (Entrez)NM_020375
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)TIGAR
Cluster EST : UnigeneHs.504545 [ NCBI ]
CGAP (NCI)Hs.504545
Alternative Splicing GalleryENSG00000078237
Gene ExpressionTIGAR [ NCBI-GEO ]   TIGAR [ EBI - ARRAY_EXPRESS ]   TIGAR [ SEEK ]   TIGAR [ MEM ]
Gene Expression Viewer (FireBrowse)TIGAR [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)57103
GTEX Portal (Tissue expression)TIGAR
Human Protein AtlasENSG00000078237-TIGAR [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9NQ88   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ9NQ88  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ9NQ88
Splice isoforms : SwissVarQ9NQ88
PhosPhoSitePlusQ9NQ88
Domaine pattern : Prosite (Expaxy)PG_MUTASE (PS00175)   
Domains : Interpro (EBI)His_Pase_superF_clade-1    His_PPase_superfam    PG/BPGM_mutase_AS   
Domain families : Pfam (Sanger)His_Phos_1 (PF00300)   
Domain families : Pfam (NCBI)pfam00300   
Domain families : Smart (EMBL)PGAM (SM00855)  
Conserved Domain (NCBI)TIGAR
DMDM Disease mutations57103
Blocks (Seattle)TIGAR
PDB (SRS)3DCY   
PDB (PDBSum)3DCY   
PDB (IMB)3DCY   
PDB (RSDB)3DCY   
Structural Biology KnowledgeBase3DCY   
SCOP (Structural Classification of Proteins)3DCY   
CATH (Classification of proteins structures)3DCY   
SuperfamilyQ9NQ88
Human Protein Atlas [tissue]ENSG00000078237-TIGAR [tissue]
Peptide AtlasQ9NQ88
HPRD12610
IPIIPI00006907   
Protein Interaction databases
DIP (DOE-UCLA)Q9NQ88
IntAct (EBI)Q9NQ88
FunCoupENSG00000078237
BioGRIDTIGAR
STRING (EMBL)TIGAR
ZODIACTIGAR
Ontologies - Pathways
QuickGOQ9NQ88
Ontology : AmiGOresponse to ischemia  bisphosphoglycerate 2-phosphatase activity  fructose-2,6-bisphosphate 2-phosphatase activity  fructose-2,6-bisphosphate 2-phosphatase activity  protein binding  intracellular  nucleus  cytoplasm  mitochondrial outer membrane  cytosol  cytosol  cytosol  fructose 2,6-bisphosphate metabolic process  autophagy  apoptotic process  cellular response to DNA damage stimulus  response to xenobiotic stimulus  response to gamma radiation  positive regulation of cardiac muscle cell apoptotic process  dephosphorylation  fructose 1,6-bisphosphate metabolic process  negative regulation of programmed cell death  regulation of pentose-phosphate shunt  positive regulation of DNA repair  negative regulation of glycolytic process  intestinal epithelial cell development  cellular response to cobalt ion  cellular response to hypoxia  negative regulation of neuron death  negative regulation of macromitophagy  regulation of response to DNA damage checkpoint signaling  positive regulation of hexokinase activity  negative regulation of glucose catabolic process to lactate via pyruvate  negative regulation of reactive oxygen species metabolic process  
Ontology : EGO-EBIresponse to ischemia  bisphosphoglycerate 2-phosphatase activity  fructose-2,6-bisphosphate 2-phosphatase activity  fructose-2,6-bisphosphate 2-phosphatase activity  protein binding  intracellular  nucleus  cytoplasm  mitochondrial outer membrane  cytosol  cytosol  cytosol  fructose 2,6-bisphosphate metabolic process  autophagy  apoptotic process  cellular response to DNA damage stimulus  response to xenobiotic stimulus  response to gamma radiation  positive regulation of cardiac muscle cell apoptotic process  dephosphorylation  fructose 1,6-bisphosphate metabolic process  negative regulation of programmed cell death  regulation of pentose-phosphate shunt  positive regulation of DNA repair  negative regulation of glycolytic process  intestinal epithelial cell development  cellular response to cobalt ion  cellular response to hypoxia  negative regulation of neuron death  negative regulation of macromitophagy  regulation of response to DNA damage checkpoint signaling  positive regulation of hexokinase activity  negative regulation of glucose catabolic process to lactate via pyruvate  negative regulation of reactive oxygen species metabolic process  
REACTOMEQ9NQ88 [protein]
REACTOME PathwaysR-HSA-5628897 [pathway]   
NDEx NetworkTIGAR
Atlas of Cancer Signalling NetworkTIGAR
Wikipedia pathwaysTIGAR
Orthology - Evolution
OrthoDB57103
GeneTree (enSembl)ENSG00000078237
Phylogenetic Trees/Animal Genes : TreeFamTIGAR
HOVERGENQ9NQ88
HOGENOMQ9NQ88
Homologs : HomoloGeneTIGAR
Homology/Alignments : Family Browser (UCSC)TIGAR
Gene fusions - Rearrangements
Fusion : MitelmanTIGAR/TSPAN9 [12p13.32/12p13.33]  
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerTIGAR [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)TIGAR
dbVarTIGAR
ClinVarTIGAR
1000_GenomesTIGAR 
Exome Variant ServerTIGAR
ExAC (Exome Aggregation Consortium)ENSG00000078237
GNOMAD BrowserENSG00000078237
Genetic variants : HAPMAP57103
Genomic Variants (DGV)TIGAR [DGVbeta]
DECIPHERTIGAR [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisTIGAR 
Mutations
ICGC Data PortalTIGAR 
TCGA Data PortalTIGAR 
Broad Tumor PortalTIGAR
OASIS PortalTIGAR [ Somatic mutations - Copy number]
Mutations and Diseases : HGMDTIGAR
BioMutasearch TIGAR
DgiDB (Drug Gene Interaction Database)TIGAR
DoCM (Curated mutations)TIGAR (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)TIGAR (select a term)
intoGenTIGAR
NCG5 (London)TIGAR
Cancer3DTIGAR(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM610775   
Orphanet
MedgenTIGAR
Genetic Testing Registry TIGAR
NextProtQ9NQ88 [Medical]
TSGene57103
GENETestsTIGAR
Target ValidationTIGAR
Huge Navigator TIGAR [HugePedia]
snp3D : Map Gene to Disease57103
BioCentury BCIQTIGAR
ClinGenTIGAR
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD57103
Chemical/Pharm GKB GenePA25506
Clinical trialTIGAR
Miscellaneous
canSAR (ICR)TIGAR (select the gene name)
Probes
Litterature
PubMed47 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineTIGAR
EVEXTIGAR
GoPubMedTIGAR
iHOPTIGAR
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Oct 12 16:17:45 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.